SCHEMBL6352335

SCHEMBL6352335

CS(=O)(=O)c1ccc(-n2nc(C(N)=O)c3ccc4ccc(NC(=O)c5cccc(Cl)c5Cl)cc4c32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.44
JAK1 P23458 3/20 0.44
MAPK14 Q16539 1/20 0.42
PCTP Q9UKL6 1/20 0.42
STARD10 Q9Y365 1/20 0.42
TYK2 P29597 2/20 0.41
JAK3 P52333 2/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAOB P27338 1/20 0.40
F2R P25116 1/20 0.40
AVPR2 P30518 1/20 0.40
GPR27 Q9NS67 1/20 0.40
MAPT P10636 3/20 0.39
GAA P10253 1/20 0.39
SMO Q99835 1/20 0.39
USP28 Q96RU2 2/20 0.39
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6354558 0.93 KMT2A (0.44) JAK2JAK1PCTPTYK2JAK3
SCHEMBL6350930 0.92 KMT2A (0.46) JAK2JAK1PCTPSTARD10RAB9A
SCHEMBL6342495 0.88 IKBKB (0.51) RAB9AMEN1KMT2AMAPTGAA
SCHEMBL6353442 0.87 CRACR2A (0.43) RAB9ANPC1KMT2AMAOBMAPT
SCHEMBL6345063 0.86 RAB9A (0.43) JAK2JAK1TYK2JAK3RAB9A
SCHEMBL6340626 0.85 KMT2A (0.55) JAK2JAK1KMT2A
SCHEMBL6340636 0.84 PTGES (0.43) MEN1KMT2AF2R
SCHEMBL6344535 0.83 KMT2A (0.54) KMT2A
SCHEMBL6345452 0.82 KMT2A (0.48) JAK2JAK1RAB9AMEN1KMT2A
SCHEMBL6343763 0.81 IKBKB (0.49) JAK2JAK1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP claimed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US claimed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO claimed
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 JAK2 26/4885JAK1 179/4885MAPK14 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.